Publications by authors named "Anabel Jimenez-Millan"
Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.
Front Endocrinol (Lausanne)
November 2023
Article Synopsis
- Semaglutide is an effective treatment for glycemic control and weight loss in type 2 diabetes (T2D) patients, including those with chronic kidney disease (CKD), showing no significant safety concerns over a 12-month period.
- In a study comparing T2D patients with and without CKD, both groups experienced reduced HbA1c levels and weight loss, although non-CKD patients lost slightly more weight.
- CKD severity had minimal impact on treatment efficacy and safety, suggesting that semaglutide can be safely used in T2D patients with varying levels of kidney function.
Background: The aim of this study is to investigate the use of once-weekly semaglutide in a real population of patients with type 2 diabetes mellitus (T2DM) over 70 years in two Spanish hospitals.
Methods: An observational, retrospective, and multicenter clinical study was designed. It included 60 patients with T2DM, with a mean age of 76.
Background: Semaglutide [glucagon-like peptide-1 receptor-agonist (GLP-1RA)] has shown nephroprotective effects in previous cardiovascular studies. However, its efficacy and safety in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) have been rarely studied.
Methods: This is a multicenter, retrospective, observational study in patients with T2D and CKD with glycosylated hemoglobin A1c (HbA1c) of 7.